consumption-dbd-data-45.html
DANMAP 2015 3D
46 / 144
danmap 2015 46 antimicrobial
consumption
in humans 5. zole (atc code p01ab01) and vancomycin (atc code a07aa09), since these constitute important systemic antibacterial treat- ment as well. their
consumption
has been included since dan- map 2014 and tables and figures were updated ten years back. tuberculostatica, antiviral and antifungal drugs are not included. 5.2
total
consumption
(primary health care and hospital care) in 2015 the
total
consumption
of antimicrobials in both sectors was 18.50 defined daily doses per 1000 inhabitants per day (
did
), close to the
total
consumption
of 2014, where a
total
of 18.58
did
was registered (figure 5.1). this corresponds to 52,691kg active compound consumed in 2015 (table a5.1 in web annex). the
total
consumption
calculated over 20 years shows no big variations for the first five years of registration from 1996 (13.40
did
) till 2000 (13.63
did
), although there was a single top with a 5% higher
consumption
in 1998. from 2000 onwards, continuously increasing trend was observed until the year 2011, where the
consumption
peaked with 19.31
did
, an overall increase of 42%.. since 2011 the
consumption
has levelled off, primarily due to minor decreases in the primary sector, corresponding to a
total
decline of 4.2% over the past four years. generally, the
total
consumption
in the 20 year period increased by 38%, from 13.40
did
in 2006 to 18.50
did
in 2015. primary health care accounts for approximately 90% of the
consumption
, thus significant changes in prescription here will markedly influence the
total
consumption
. among the scandinavian countries, the danish
consumption
during the past 20 years was generally the lowest during the 1990s. however, continuously increasing trends in denmark and simultaneously decreasing trends in sweden, resulted in denmark having the highest
consumption
of the three countries in 2014 and sweden the lowest (www.ecdc. europa.eu/en; data & tools, esac-database ). for norway the
consumption
fluctuated between 16 and 18
did
during the 20 years, showing decreasing trends for the last three years. in 2015 the
total
consumption
of antimicrobials was 13.6
did
in sweden and 18,8
did
in norway. the norwegian national action plan from 2015 aiming for a 30% reduction in the
total
consumption
((with 2012 as the reference point) will expectantly result in a much lower
consumption
in the years to come. at the european level, denmark reports a comparatively low
consumption
of antimicrobial agents, specifically character- ized by the proportionally high
consumption
of penicillins (esac-net 2014). atc group (a) therapeutic group year 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 j01aa tetracyclines 1,07 0.98 0.98 93 0.98 0.99 1.04 1.07 1.17 1.28 j01ca penicillins with extended spectrum 2.50 2.39 2.39 2.29 2.29 2.47 2.51 2.52 2.63 2.79 j01ce beta-lactamase sensitive penicillins 4.50 4.57 4.81 4.48 4.69 4.91 5.00 5.07 5.20 5.28 j01cf beta-lactamase resistant penicillins 0.30 0.34 0.40 0.48 0.52 0.65 0.77 0.85 0.92 0.97 j01cr combinations of penicillins, including beta- lactamase inhibitors 0.00 0.02 0.03 0.02 0.02 0.03 0.04 0.05 0.06 0.08 j01d cephalosporins and other ?-lactam antibiotics 0.00 0.02 0.03 0.02 0.02 0.03 0.03 0.02 0.02 0.03 j01ea trimethoprim and derivatives 0.30 0.30 0.32 0.32 0.33 0.35 0.36 0.38 0.41 0.44 j01eb short-acting sulfonamides 0.40 0.41 0.41 0.38 0.38 0.36 0.36 0.36 0.36 0.35 j01ee combinations of sulfonamides and trimethoprim, including derivatives 0.10 0.08 0.04 0.03 0.04 0.03 0.02 0.03 0.00 0.00 j01fa macrolides 1.90 2.03 2.28 2.17 2.02 2.10 2.15 2.13 2.23 2.41 j01ff lincosamides 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 j01gb aminoglycosides 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.00 0.01 j01ma fluoroquinolones 0.20 0.22 0.23 0.20 0.15 0.17 0.18 0.25 0.28 0.33 j01xa glycopeptides 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 j01xb polymyxins 0.00 0.03 0.02 0.03 0.03 0.02 0.02 0.02 0.02 0.02 j01xc steroid antibacterials (kombination fusidic acid) 0.00 0.02 0.02 0.02 0.02 0.01 0.01 0.01 0.01 0.01 j01xe nitrofuran derivatives (nitrofurantoin) 0.04 0.35 0.36 0.36 0.38 0.39 0.41 0.42 0.43 0.45 j01xx other antibacterials (methenamine >99%) 0.50 0.46 0.43 0.40 0.36 0.33 0.34 0.32 0.30 0.28 j01xd and p01ab* nitroimidazole derivatives (metronidazole) 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 j01+p01ab antibacterial agents for systemic use (
total
) 12.20 12.24 12.76 12.15 12.21 12.85 13.26 13.53 14.06 14.96 table 5.1a.
consumption
of antimicrobial agents for systemic use in primary health care (ddd/1000 inhabitant-days), denmark, 1996 - 2005 danmap 2015 a) from the 2015 edition of the anatomical therapeutic chemical (atc) classification system *) all metronidazole preparations, formerly only listed as j01xd, 10 years retrospective data included in the danmap report since 2014
2015-consumption-did-47.html
